Real-World Effectiveness and Metabolic Effects of Upadacitinib in Rheumatoid Arthritis after Tumor Necrosis Factor Inhibitor Failure

Year 2026, Volume: 53 Issue: 1, 179 - 190, 10.03.2026

Zeynel Abidin Akar Dilan Yıldırım Ömer Karakoyun , Mehmet Çağlayan

https://doi.org/10.5798/dicletip.1906479

https://izlik.org/JA68HZ74FK

Abstract

Objectives: To evaluate the real-world effectiveness and laboratory impact of upadacitinib in patients with rheumatoid arthritis (RA) who had an inadequate response to at least one tumor necrosis factor inhibitor (TNFi), with a specific focus on clinical disease activity, inflammatory biomarkers, and metabolic indices.
Methods: This single-center, retrospective, real-world study included 82 patients with RA who initiated upadacitinib (15 mg/day) following TNFi failure. Demographic data, disease characteristics, Disease Activity Score in 28 joints (DAS28-CRP), inflammatory markers (CRP and ESR), hematological indices, liver enzymes, and a comprehensive lipid profile were analyzed. In addition, the triglyceride–glucose (TyG) index and the HDL-to-monocyte ratio were calculated as markers of metabolic and cardiovascular risk. Clinical and laboratory parameters were compared between baseline and Week 12 using paired-sample statistical tests.
Results: At Week 12, the DAS28-CRP score significantly decreased from 5.4 to 2.9 (p < 0.001), with 80.5% of patients achieving low disease activity or remission. While total cholesterol, LDL-C, and HDL-C levels increased (all p < 0.001), the HDL/monocyte ratio improved significantly by 7.7% (p = 0.012). A moderate negative correlation was observed between the change in DAS28-CRP and the change in HDL/monocyte ratio (rho = -0.42, p = 0.001). Creatine kinase (CK) levels showed a modest but statistically significant increase (+8.1%, p = 0.025); however, values remained within normal reference ranges and were not associated with muscular symptoms or treatment discontinuation. Clinical efficacy was consistent across rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) subgroups. No serious adverse events or treatment discontinuations due to adverse events were observed during the 12-week follow-up period.
Conclusions: In this difficult-to-treat, real-world cohort of TNFi-refractory RA patients, upadacitinib demonstrated rapid and robust clinical effectiveness. Despite the anticipated elevations in lipid parameters, the concomitant increase in HDL cholesterol, the stable TyG index, and the marked suppression of systemic inflammation suggest no evident short-term deterioration in metabolic parameters. However, given the 12-week follow-up duration, these metabolic findings should be considered exploratory and hypothesis-generating rather than definitive regarding cardiovascular or metabolic safety. These results support upadacitinib as an effective therapeutic option for anti-TNF–resistant RA in routine clinical practice.

Keywords

Upadacitinib; Rheumatoid arthritis , Janus kinase inhibitors; Real-world evidence , Lipid paradox; Triglyceride–glucose index

Ethical Statement

The study protocol was approved by the Dicle University Medical Faculty Ethics Committee for Noninterventional Studies (Approval No: 6; Date: 24/12/2025).

TNF İnhibitörü Başarısızlığı Sonrası Romatoid Artritte Upadasitinibin Gerçek Yaşam Etkinliği ve Metabolik Etkileri

https://izlik.org/JA68HZ74FK

Abstract

Amaç: En az bir tümör nekroz faktörü inhibitörüne (TNFi) yetersiz yanıt veren romatoid artrit (RA) hastalarında upadasitinibin gerçek yaşam koşullarındaki etkinliğini ve laboratuvar etkilerini; özellikle klinik hastalık aktivitesi, inflamatuvar biyobelirteçler ve metabolik göstergeler üzerindeki etkilerini değerlendirmek.
Yöntemler: Bu tek merkezli, retrospektif, gerçek yaşam çalışmasına TNFi başarısızlığı sonrası upadasitinib (15 mg/gün) başlanan 82 RA hastası dahil edildi. Demografik veriler, hastalık özellikleri, 28 eklemde Hastalık Aktivite Skoru (DAS28-CRP), inflamatuvar belirteçler (CRP ve ESR), hematolojik indeksler, karaciğer enzimleri ve kapsamlı lipid profili analiz edildi. Ayrıca metabolik ve
kardiyovasküler risk belirteçleri olarak trigliserid–glukoz (TyG) indeksi ve HDL kolesterolün mutlak monosit sayısına oranı olarak tanımlanan HDL/monosit oranı hesaplandı. Klinik ve laboratuvar parametreleri başlangıç ile 12. hafta arasında eşleştirilmiş örneklem istatistiksel testleri kullanılarak karşılaştırıldı.
Bulgular: 12. haftada DAS28-CRP skoru 5,4’ten 2,9’a anlamlı olarak azaldı (p < 0,001) ve hastaların %80,5’inde düşük hastalık aktivitesi veya remisyon sağlandı. Toplam kolesterol, LDL-K ve HDL-K düzeylerinde artış gözlenmesine rağmen (tümü p < 0,001), HDL/monosit oranı %7,7 oranında anlamlı bir iyileşme gösterdi (p = 0,012). DAS28-CRP’deki değişim ile HDL/monosit oranındaki
değişim arasında orta düzeyde negatif bir korelasyon saptandı (rho = -0,42; p = 0,001). Kreatin kinaz (CK) düzeylerinde %8,1 oranında istatistiksel olarak anlamlı bir artış izlenmiş (p = 0,025) olmakla birlikte, bu artış klinik referans aralıkları içinde kalmış ve tedavi kesilmesini gerektirmemiştir. Klinik etkinlik romatoid faktör (RF) ve anti-CCP alt gruplarında tutarlıydı. On iki haftalık takip süresince
ciddi advers olay gözlenmemiş ve tedavi kesilmesine yol açan yan etki bildirilmemiştir.
Sonuç: TNFi’ye dirençli, tedavisi zor bu gerçek yaşam RA kohortunda upadasitinib hızlı ve güçlü bir klinik etkinlik göstermiştir. Beklenen lipid parametre artışlarına rağmen, HDL kolesteroldeki eş zamanlı yükselme, TyG indeksinin stabil kalması ve sistemik inflamasyonun belirgin baskılanması kısa dönemde metabolik parametrelerde belirgin bir bozulma olmadığını düşündürmektedir.
Bununla birlikte, 12 haftalık takip süresi kardiyovasküler veya metabolik güvenlik açısından kesin çıkarımlar yapmak için yeterli değildir ve bu bulgular keşifsel nitelikte değerlendirilmelidir. Bu sonuçlar, anti-TNF’ye dirençli RA hastalarında upadasitinibin etkili bir tedavi seçeneği olduğunu desteklemektedir.

Keywords

Upadasitinib; Romatoid artrit , Janus kinaz inhibitörleri; , Gerçek yaşam verileri; Lipid paradoksu; Trigliserid– glukoz indeksi.

References

• 1. Smolen J., Aletaha D., Barton A. et al. Rheumatoid arthritis. Nat Rev Dis Primers 4, 18001 (2018). https://doi.org/10.1038/nrdp.2018.1
• 2. Kerschbaumer A, Sepriano A, Smolen JS, et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020 Jun;79(6):744-59. doi: 10.1136/annrheumdis-2019-216656.
• 3. Smolen JS, Landewé RBM, Bergstra SA. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3-18. doi: 10.1136/ard-2022-223356. Epub 2022 Nov 10. Erratum in: Ann Rheum Dis. 2023 Mar;82(3):e76.doi: 10.1136/ard-2022-223356corr1.
• 4. Sanmartí R, Corominas H. Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review. J Clin Med. 2023 Feb 21;12(5):1734. doi: 10.3390/jcm12051734.
• 5. Serhal L, Edwards CJ. Upadacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2019 Jan;15(1):13-25. doi: 10.1080/1744666X.2019.1544892.
• 6. Charles-Schoeman C, Buch MH, Dougados M, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2023 Jan;82(1):119-29. doi: 10.1136/ard-2022-222259.
• 7. Ytterberg SR, Bhatt DL, Mikuls TR, et al; ORAL Surveillance Investigators. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022 Jan 27;386(4):316-26.doi: 10.1056/NEJMoa2109927.
• 8. Makris A, Barkas F, Sfikakis PP, Liberopoulos E, Agouridis AP. The Effect of Upadacitinib on Lipid Profile and Cardiovascular Events: A Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2022 Nov 22;11(23):6894. doi: 10.3390/jcm11236894.
• 9. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011 Mar;70(3):482-7. doi: 10.1136/ard.2010.135871.
• 10. Romo-Cordero A, González-Sierra M, Quevedo-Abeledo JC, et al. The Ratio of Monocytes to HDLCholesterol Is Associated with Cardiovascular Risk and Insulin Resistance in Patients with Rheumatoid Arthritis. Life (Basel). 2023 Sep 29;13(10):1995. doi: 10.3390/life13101995.
• 11. Tao LC, Xu JN, Wang TT, Hua F, Li JJ. Triglycerideglucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol. 2022 May 6;21(1):68. doi: 10.1186/s12933-022-01511-x.
• 12. Östör A, Feist E, Sidiropoulos P, Avouac J, et al. Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in realworld practice: 1-year outcomes from the UPHOLD observational study. Arthritis Res Ther. 2025 Apr 10;27(1):84. doi: 10.1186/s13075-025-03528-5.
• 13. Youssef P, Ciciriello S, Tahir T, Leadbetter J, et al. Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis. Rheumatol Ther. 2025 Feb;12(1):173-202. doi:10.1007/s40744-024-00736-4.
• 14. Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018 Jun 23;391(10139):2503-12. doi:10.1016/S0140-6736(18)31115-2.
• 15. van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebocontrolled, phase 2/3 trial. Lancet. 2019 Dec 7;394(10214):2108-17. doi: 10.1016/S0140-6736(19)32534-6.
• 16. Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECTBEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018 Jun 23;391(10139):2513-24. doi: 10.1016/S0140-6736(18)31116-4.
• 17. Baldi C, Gentileschi S, Li Gobbi F, et al. Real-world effectiveness and retention rate of upadacitinib in patients with rheumatoid arthritis: results from a multicentre study. Clin Exp Med. 2025 Feb 5;25(1):50. doi: 10.1007/s10238-025-01578-2.
• 18. Behl T, Kaur I, Sehgal A, et al. The Lipid Paradox as a Metabolic Checkpoint and Its Therapeutic Significance in Ameliorating the Associated Cardiovascular Risks in Rheumatoid Arthritis Patients. Int J Mol Sci. 2020 Dec 14;21(24):9505. doi: 10.3390/ijms21249505.
• 19. Li N, Gou ZP, Du SQ,et al. Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysis. Clin Rheumatol. 2022 Mar;41(3):677-88. doi: 10.1007/s10067-021-06003-z.
• 20. Isufi D, Javanmardi N, Jensen MB, et al. Risk of Dyslipidemia Associated With Oral Janus Kinase Inhibitors: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Int J Dermatol. 2025 Oct 29. doi: 10.1111/ijd.70122.
• 21. Chikhoune L, Poggi C, Moreau J, et al. JAK inhibitors (JAKi): Mechanisms of action and perspectives in systemic and autoimmune diseases. Rev Med Interne. 2025 Feb;46(2):89-106. doi: 10.1016/j.revmed.2024.10.452.
• 22. Elazab SA, Elsayed WE, Alrahim NM, et al. Relationship between Triglyceride-Glucose Index and Disease Activity and Subclinical Atherosclerosis in Rheumatoid Arthritis. Curr Rheumatol Rev. 2024;20(2):191-9. doi: 10.2174/0115733971259984230922054439.
• 23. Charles-Schoeman C, Giles JT, Lane NE, et al. Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years. Rheumatol Ther. 2024 Feb;11(1):157-75. doi: 10.1007/s40744-023-00624-3.
• 24. Chai R, Li X, Shen W, et al. Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis. Front Immunol. 2025 Jul 1;16:1586792. doi: 10.3389/fimmu.2025.1586792.
• 25. Zhang C, Fu Z, Liu J, et al. Safety profile and dosedependent adverse events of upadacitinib in randomized clinical trials: a systematic review and meta-analysis. Front Pharmacol. 2025 Jun 23;16:1598972. doi: 10.3389/fphar.2025.1598972.